Explore potential applications of CertisAI across therapeutic modalities – from small molecules to antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and peptides – and demonstrate how this powerful computational tool can bring greater certainty to early development decisions and inform drug repurposing or label expansion efforts.
